PAP 2023: Corey Ford Discusses Experience in Tackling Reimbursement Challenges at Access PAP 2023

New research finds that nearly half of the racial and ethnic disparities in outpatient COVID-19 antiviral prescriptions stem from encounter-level care barriers, such as limited access to rapid tests and telehealth, which emphasizes the need for systemic and practice-level reforms.

Alice Valder Curran outlines the steps manufacturers should take to better prepare for upcoming executive actions on drug pricing and market access.

In the third part of his Pharma Commerce video interview, Marschall Runge, MD, PhD, dean of the University of Michigan Medical School and author of The Great Healthcare Disruption, proposes ways to ensure both fiscal responsibility and the sustainability of hospital funding.

Renier Brentjens, MD, PhD outlines the evolution of the space, while offering ways to boost patient access to these treatments.

The US president says the levies on pharmaceutical imports are imminent, but won’t take effect for a year to a year and a half.

Amid the push for reshoring and fiscal reform, the tariffs are part of a broader effort to rebalance trade and fund domestic initiatives, as the pharma sector awaits potential levies of its own.